Use of L-ornithine-L-aspartate in patients with non-alcoholic fatty liver disease
Abstract
Complex mechanisms of therapy of non-alcoholic fatty liver disease, the role of L-ornithine-L-aspartate in the level of human growth hormone, with physical loads of various intensify, stress, fatigue, alcohol intake and sleep disorders are considered in the article. The results of the study of clinical efficacy of L-orni-thine-L-aspartate in 96 patients with non-alcoholic steatohepatitis are presented.
About the Author
E. I. Sas
Military Medical Academy n. a. S.M. Kirov of the Ministry of Defense of Russia; Saint Petersburg State Pediatric University
Russian Federation
Russian Federation
References
1. Thompson G. R. The proving of the lipid hypothesis. Current Opinion in Lipidology. 10th Anniversary issue. 1999; 10(3): 201-205.
2. Danik M. Martirosyan (Ed): Functional Foods and Chronic Diseases: Science and Practice. Food Science Publisher; 2011.
3. Адашева Т. В. Метаболический синдром - основы патогенетической терапии. Леч. врач. 2003; 10: 5-7.
4. Клинико-морфологическая диагностика хронических заболеваний печени в сочетании с патологией сердечно-сосудистой системы. Методические рекомендации по теме НИР 4.99.241.п. 12). СПб., 2000.
5. Лазебник А. Б. и др. Клинико-морфологические изменения печени при атерогенной дислипидемии и при лечении статинами. Тер. арх. 2003; 75 (8): 51-4.
6. Морозов И. А. Метаболические аспекты морфогенеза липидных включений в печени. Экспер. и клин. гастроэнтерол. 2003; 1: 60-4.
7. Jorge C. Correia, Duarte M. S. Ferreira Intercellular: local and systemic actions of skeletalmuscle PGC- 1s. Trends in Endocrinology & Metabolism. - 2015 26, S. 305-314.
8. Lambert M. I., Hefer J. A., Millar R. P., Macfarlane P. W. Failure of commercial oral amino acid supplements to increase serum growth hormone concentrations in male body-builders. Int J Sport Nutr. 1993. - Vol. 3. S 298-305.
9. Chromiak J. A., Antonio J. Use of amino acids as growth hormone-releasing agents by athletes. Nutrition. 2002. - Vol. 8. S 657-661.
Review
For citations:
Sas E.I. Use of L-ornithine-L-aspartate in patients with non-alcoholic fatty liver disease. Medical alphabet. 2018;1(7):17-21. (In Russ.)
Views:
604
Email this article 